Lei Jiang

US Patent:

8349883, Jan 8, 2013

Filed:

Apr 8, 2011

Appl. No.:

13/082956

Inventors:

Michael D. Shultz - Cambridge MA, US
Christine Hiu-Tung Chen - Cambridge MA, US
Young Shin Cho - Cambridge MA, US
Lei Jiang - Cambridge MA, US
Jianmei Fan - Cambridge MA, US
Gang Liu - Cambridge MA, US
Dyuti Majumdar - Cambridge MA, US
Jianke Li - Cambridge MA, US

Assignee:

Novartis AG - Basel

International Classification:

A61K 31/4162
A61K 31/4155

US Classification:

514403, 514406

Abstract:

The present teachings relate to compounds of Formula I:The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.

US Patent:

20100022514, Jan 28, 2010

Filed:

Dec 17, 2007

Appl. No.:

12/519319

Inventors:

Young Shin Cho - Cambridge MA, US
Lei Jiang - Cambridge MA, US
Michael Shultz - Cambridge MA, US

International Classification:

A61K 31/4035
C07D 209/44
C07D 403/06
C07D 401/12
C07D 471/04
C07D 217/04
A61K 31/55
A61K 31/4439
A61K 31/4178
A61K 31/437
A61K 31/472
A61K 31/4725
A61P 35/00
A61P 37/00
A61P 25/00

US Classification:

51421301, 548482, 548455, 540594, 540593, 5462771, 5483121, 546121, 546146, 514416, 514414, 51421701, 514339, 514397, 514300, 514307

Abstract:

The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.

US Patent:

20230112986, Apr 13, 2023

Filed:

Jul 21, 2022

Appl. No.:

17/813984

Inventors:

- Cambridge MA, US
- Pamplona, ES
Kerry BENENATO - Sudbury MA, US
Lei JIANG - Cambridge MA, US
Iain MCFADYEN - Arlington MA, US
Ellalahewage Sathyajith KUMARASINGHE - Harvard MA, US
Antonio FONTANELLAS ROMA - Pamplona, ES
Pedro BERRAONDO LOPEZ - Pamplona, ES
Matias Antonio AVILA ZARAGOZA - Pamplona, ES
Lin Tung GUEY - Lexington MA, US
Staci SABNIS - Medford MA, US

Assignee:

ModernaTX, Inc. - Cambridge MA
Fundacion Para La Investigacion Medica Aplicada - Pamplona

International Classification:

A61K 38/45
C12N 9/10
A61K 48/00
A61P 7/08
C12N 15/88

Abstract:

The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).

US Patent:

20200085916, Mar 19, 2020

Filed:

May 18, 2017

Appl. No.:

16/302339

Inventors:

- Cambridge MA, US
- Pamplona, ES
Kerry Benenato - Cambridge MA, US
Vladimir Presnyak - Manchester NH, US
Lei Jiang - Cambridge MA, US
Iain McFadyen - Medford MA, US
Ellalahewage Sathyajith Kumarasinghe - Cambridge MA, US
Antonio Fontanellas Roma - Pamplona, ES
Pedro Berraondo Lopez - Pamplona, ES
Matias Antonio Avila Zaragoza - Pamplona, ES
Lin Tung Guey - Lexington MA, US
Staci Sabnis - Cambridge MA, US

International Classification:

A61K 38/45
C12N 9/10
C12N 15/88
A61K 48/00
A61P 7/08

Abstract:

The invention relates to mRNA therapy for the treatment of Acute Intermittent Porphyria (AIP). mRNAs for use in the invention, when administered in vivo, encode human porphobilinogen deaminase (PBGD), isoforms thereof, functional fragments thereof, and fusion proteins comprising PBGD. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to affect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of PBGD expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient PBGD activity in subjects, namely porphobilinogen and aminolevulinate (PBG and ALA).